FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2603335388> ?p ?o ?g. }

• W2603335388 abstract "e14633 Background: Kyushu Study group of Clinical Cancer (KSCC) conducted the phase II study that evaluated the neoadjuvant chemotherapy for optimally-unresectable colorectal liver-limited metastases (KSCC0802, Samura et al, J Clin Oncol 30:4s, 2012). We carried out a central review for the purpose of obtaining an objective assessment of how resectability changed during treatment. Methods: We reviewed the CT or MRI images before and after protocol treatment, according to the method of CELIM study. A surgical review was done by five independent hepatobiliary special surgeons from five different centers. A resectability was reviewed based on radiological images only. Individual surgeons were blinded to the time when the CT scan was taken. The surgeons voted for (1) curative resection, (2) exploratory laparotomy with aim of resection (3) borderline resectable with chemotherapy preferred first, (4) unresectable, (5) non-evaluable. Patients were considered resectable if 50% (non-evaluable is excluded) or more of surgeons voted for categories (1) and (2), and images were considered evaluable if more than three surgeons voted with categories (1)–(4). Results: In KSCC0802 study, of the 40 pts. enrolled from Sept. 9 2008 to Aug. 10 2010. The number of cases to intent operation after chemotherapy was 17 (42.5%), and the actual liver resectability was 16/40 (40.0 %). The number of R0 cases was 10 pts. . In total, 77 images were presented for this central review. Only three follow-up scans were not available. Following review, 17 (42.5%) of 40 patients were judged to be resectable after chemotherapy, compared with 14 (35.0%) patients at baseline. Of 36 cases in which both imaging studies were available to be evaluated before and after chemotherapy, 7 cases (19.4%) judged as unresectable before chemotherapy were finally determined as resectable after chemothrerapy. Conclusions: With the central review by 5 independent liver surgeons, the resectability was fairly determined before and after chemotherapy. mFOLFOX6 with Bevacizumab regimen is safe and effective for unresectable liver limited-metastases from colorectal cancer, and might be to lead the liver resectability. Clinical trial information: UMIN000001308." @default.
• W2603335388 created "2017-04-07" @default.
• W2603335388 creator A5004420462 @default.
• W2603335388 creator A5008493036 @default.
• W2603335388 creator A5012550681 @default.
• W2603335388 creator A5024742184 @default.
• W2603335388 creator A5032856038 @default.
• W2603335388 creator A5033527507 @default.
• W2603335388 creator A5035399792 @default.
• W2603335388 creator A5036330211 @default.
• W2603335388 creator A5037778606 @default.
• W2603335388 creator A5043888846 @default.
• W2603335388 creator A5049313696 @default.
• W2603335388 creator A5051051662 @default.
• W2603335388 creator A5063331240 @default.
• W2603335388 creator A5063723368 @default.
• W2603335388 creator A5067072266 @default.
• W2603335388 creator A5081874060 @default.
• W2603335388 date "2013-05-20" @default.
• W2603335388 modified "2023-09-26" @default.
• W2603335388 title "A central review of resectability of optimally unresectable colorectal liver metastases following neoadjuvant chemotherapy (KSCC0802)." @default.
• W2603335388 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.e14633" @default.
• W2603335388 hasPublicationYear "2013" @default.
• W2603335388 type Work @default.
• W2603335388 sameAs 2603335388 @default.
• W2603335388 citedByCount "0" @default.
• W2603335388 crossrefType "journal-article" @default.
• W2603335388 hasAuthorship W2603335388A5004420462 @default.
• W2603335388 hasAuthorship W2603335388A5008493036 @default.
• W2603335388 hasAuthorship W2603335388A5012550681 @default.
• W2603335388 hasAuthorship W2603335388A5024742184 @default.
• W2603335388 hasAuthorship W2603335388A5032856038 @default.
• W2603335388 hasAuthorship W2603335388A5033527507 @default.
• W2603335388 hasAuthorship W2603335388A5035399792 @default.
• W2603335388 hasAuthorship W2603335388A5036330211 @default.
• W2603335388 hasAuthorship W2603335388A5037778606 @default.
• W2603335388 hasAuthorship W2603335388A5043888846 @default.
• W2603335388 hasAuthorship W2603335388A5049313696 @default.
• W2603335388 hasAuthorship W2603335388A5051051662 @default.
• W2603335388 hasAuthorship W2603335388A5063331240 @default.
• W2603335388 hasAuthorship W2603335388A5063723368 @default.
• W2603335388 hasAuthorship W2603335388A5067072266 @default.
• W2603335388 hasAuthorship W2603335388A5081874060 @default.
• W2603335388 hasConcept C121608353 @default.
• W2603335388 hasConcept C126322002 @default.
• W2603335388 hasConcept C143998085 @default.
• W2603335388 hasConcept C2776694085 @default.
• W2603335388 hasConcept C2778292576 @default.
• W2603335388 hasConcept C526805850 @default.
• W2603335388 hasConcept C530470458 @default.
• W2603335388 hasConcept C71924100 @default.
• W2603335388 hasConceptScore W2603335388C121608353 @default.
• W2603335388 hasConceptScore W2603335388C126322002 @default.
• W2603335388 hasConceptScore W2603335388C143998085 @default.
• W2603335388 hasConceptScore W2603335388C2776694085 @default.
• W2603335388 hasConceptScore W2603335388C2778292576 @default.
• W2603335388 hasConceptScore W2603335388C526805850 @default.
• W2603335388 hasConceptScore W2603335388C530470458 @default.
• W2603335388 hasConceptScore W2603335388C71924100 @default.
• W2603335388 hasLocation W26033353881 @default.
• W2603335388 hasOpenAccess W2603335388 @default.
• W2603335388 hasPrimaryLocation W26033353881 @default.
• W2603335388 isParatext "false" @default.
• W2603335388 isRetracted "false" @default.
• W2603335388 magId "2603335388" @default.
• W2603335388 workType "article" @default.